Company intelligence / Profile preview
Grünenthal GmbH
Aachen, North Rhine-Westphalia, Germanygrunenthal.com ↗
- Ownership
- Private
- Employees
- ~4400
- Development stage
- Other
01
Overview
Grünenthal is a global leader in pain management with multiple commercial products and ongoing clinical trials. Recent developments include completing recruitment for QUTENZA® post-surgical neuropathic pain trial in July 2024 and beginning first-in-human trials with a NOP agonist for pain management in October 2024[8].
- Therapeutic areas
- ImmunologyNeurologyRheumatology
- Modalities
- Small moleculestopical patches
- Industry
- Pharma
02
Drug pipeline
35 assets34 more assets in the full pipeline.
03
Partnerships
Kyowa Kirin International (joint venture collaboration)[8]
Beyond the preview
Go deeper on Grünenthal GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grünenthal GmbH.